公司資料
Adlai Nortye Ltd. 股價、新聞與催化劑
- 股票代碼:
- ANL
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
13.34 USD (+0.68%)
收盤價
最後更新: 2026年8月17日
746M USD
市值
股價為何變動
Following the latest company update, “Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress”, ANL closed up 3.03% at $13.25 on Aug 14, 2026. The move occurred in the trading session associated with this earnings update.
公司概覽
業務概覽
Annovis Bio is a biotechnology company focused on neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Its story centers on trying to address difficult CNS diseases with a focused molecular approach.
所在地與產業分類
Annovis is headquartered in the United States and listed on NASDAQ. It sits in neuroscience biotechnology.
商業模式特徵
The company depends on clinical proof, translational confidence, and the ability to keep a narrow pipeline funded. Investors usually watch early data and whether the biology can support a meaningful CNS thesis.
生技產業定位
Annovis occupies a high-risk neurodegeneration niche within biotech. The stock is highly dependent on whether the company can show a real disease-modifying effect.
未來催化劑
- Adlai Nortye’s catalysts are its oncology pipeline and any clinical update that clarifies whether the company can still build a meaningful development story. The stock remains early and data-dependent.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。